Biocept Inc (NASDAQ: BIOC) is having yet another incredibly strong start to the trading session in the market this morning, following the more than 90% gains posted by the stock yesterday. The movement is ultimately the result of a commercial product launch that’s leading to excitement among investors. Today, we’ll talk about:
- Why investors are so excited about the product launch;
- what we’re seeing from BIOC stock as a result; and
- what we’ll be watching for ahead.
Why Investors Are So Excited About The BIOC Target Selector Launch
As mentioned above, Biocept is extending its gains in the premarket hours this morning after announcing a product launch yesterday. In a press release, the company announced the commercial launch of its Target Selector NGS Lung Panel.
This panel is a multi-gene liquid biopsy panel that has been specifically developed for the detection of lung cancer. In the release, BIOC said tha tthe panel will be marketed to physicians and researchers, and can be used to detect and monitor actionable biomarkers associated with lung cancer.
So, why are investors so excited?
Well, lung cancer is the leading cause of death in the United States. This Target Selector panel could help treat these patients in a big way. You see, timely and accurate molecular characterization of a patient’s cancer for selection of the best possible therapy has proven to extend overall survival.
However, many patients do not undergo molecular profiling due to the lack of availability of tissue for molecular testing. With the Target Selector, there is no more need for tissue as the biopsy is a liquid one. This means that a larger number of patients will have access to more meaningful treatment options.
Considering this, the Target Selector could prove to be a blockbuster product as it provides a solution to a key problem in the treatment of lung cancer. In a statement, Michael Nall, President and CEO at BIOC, had the following to offer:
We are very pleased to launch our first multi-gene liquid biopsy panel to physicians and researchers in both academic centers and the pharmaceutical industry.
This new solution makes Biocept the only commercial liquid biopsy company that can offer customers the flexibility to order either a customized single biomarker assay or a larger NGS-based liquid biopsy test panel for use when more comprehensive testing is desired.
This new offering complements our existing Target Selector™ testing platform, which focuses on delivering actionable and cost-effective biomarker information to address needs of physicians, healthcare systems and payors as they develop personalized treatment protocols for patients diagnosed with cancer.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to work in the market is that the news leads to moves. When it comes to Biocept, the news proved to be incredibly positive.
With the launch of the Target Selector, the company is not only launhcing a product that has the potential to generate significant revenue, it is launching a product that has the ability to solve a very real problem in the treatment of lung cancer. At the end of the day, this is a big step for a small company like Biocept.
So, it’s not surprising to see that the excitement among investors is continuing. As is just about always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (8:00), BIOC is trading at $2.05 per share after a gain of $0.45 per share or 28.12% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on BIOC. In particular, we’re interested in following the story surrounding the company’s work to commercialize the Target Selector and excited to see the revenue growth that this commercialization process results in. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!